Volibris contraindicated in idiopathic pulmonary fibrosis

The new contraindication follows the early termination of the ARTEMIS-IPF study, which was investigating the potential of ambrisentan to slow disease progression in patients with IPF. Evaluation of the primary endpoint components indicated higher rates of respiratory hospitalisation, mortality and decreases in respiratory function in patients who received ambrisentan than in those on placebo.

Review patients

Patients with IPF who are currently receiving ambrisentan should be carefully assessed and alternative therapies should be considered.

View Volibris drug record

Further information: GlaxoSmithKline

Follow MIMS on Twitter